Zogenix defends Zohydro


In response to congressional activity seeking a withdrawal of the recently-approved Zohydro (hydrocodone), Zogenix publishes its response to yesterday's hearing.

Zohydro's potency is equivalent to other commercially available pain pills but without acetaminophen.

In terms of maximum strength per pill, all other extended-release opioids have a higher dosage strength than Zohydro.

The company offers educational tools and safeguards to ensure the safe use of Zohydro in addition to the FDA-mandated REMS.

The company has established an External Safe Use Board of Experts to monitor the use of the product.

Sales representatives are not compensated on volume sales.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs